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Nuclear-encoded factors involved in
post-transcriptional processing and
modification of mitochondrial tRNAs
in human disease
Christopher A. Powell , Thomas J. Nicholls † and Michal Minczuk*
Mitochondrial Genetics, Mitochondrial Biology Unit, Medical Research Council, Cambridge, UK
The human mitochondrial genome (mtDNA) encodes 22 tRNAs (mt-tRNAs) that are
necessary for the intraorganellar translation of the 13 mtDNA-encoded subunits of the
mitochondrial respiratory chain complexes. Maturation of mt-tRNAs involves 5′ and
3′ nucleolytic excision from precursor RNAs, as well as extensive post-transcriptional
modifications. Recent data suggest that over 7% of all mt-tRNA residues in mammals
undergo post-transcriptional modification, with over 30 different modified mt-tRNA
positions so far described. These processing and modification steps are necessary for
proper mt-tRNA function, and are performed by dedicated, nuclear-encoded enzymes.
Recent growing evidence suggests that mutations in these nuclear genes (nDNA),
leading to incorrect maturation of mt-tRNAs, are a cause of human mitochondrial
disease. Furthermore, mtDNA mutations in mt-tRNA genes, which may also affect
mt-tRNA function, processing, and modification, are also frequently associated with
human disease. In theory, all pathogenic mt-tRNA variants should be expected to
affect only a single process, which is mitochondrial translation, albeit to various extents.
However, the clinical manifestations of mitochondrial disorders linked to mutations
in mt-tRNAs are extremely heterogeneous, ranging from defects of a single tissue
to complex multisystem disorders. This review focuses on the current knowledge of
nDNA coding for proteins involved in mt-tRNA maturation that have been linked to
human mitochondrial pathologies. We further discuss the possibility that tissue specific
regulation of mt-tRNA modifying enzymes could play an important role in the clinical
heterogeneity observed for mitochondrial diseases caused by mutations in mt-tRNA
genes.
Keywords: mitochondria, tRNA, RNA modification, RNA processing, post-transcriptional regulation, mitochon-
drial disease
Introduction
Mitochondria operate a dedicated molecular apparatus to maintain and express their genome.
Mitochondrial DNA (mtDNA) encodes 13 vital subunits of the oxidative phosphorylation
(OXPHOS) system, the ultimate stage of aerobic cellular energy production. Expression of mtDNA
is therefore essential for proper cellular function. Recent research has identified defects in mtDNA
expression that are associated with an ever growing and diverse group of human disorders
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characterized by impaired mitochondrial respiration
(Nicholls et al., 2013; Boczonadi and Horvath, 2014). Follow-up
studies of patients with respiratory chain disorders, in combina-
tion with basic research approaches, has led to the identification
of many novel regulatory factors and pathways involved in
mitochondrial gene expression. Nonetheless, establishing how
defects in these processes contributes to human disease still
constitutes a major challenge (Vafai and Mootha, 2012).
The human mitochondrial transcriptome consists of the
following key components: two ribosomal RNAs (mt-rRNAs)
that are a part of the mitochondrial ribosome, a set of 22
transfer RNAs (mitochondrially encoded tRNAs, mt-tRNAs)
and 11 messenger RNAs (mt-mRNAs) coding for the thir-
teen aforementioned subunits of the OXPHOS complexes
(Rorbach and Minczuk, 2012). All of the numerous proteins nec-
essary for mitochondrial RNA synthesis, endonucleolytic pro-
cessing, post-transcriptional modifications, aminoacylation, sta-
bility regulation, and turnover as well as biogenesis of the mito-
chondrial ribosome and translation within the organelle are
encoded by nuclear genes (nDNA) and imported tomitochondria
upon translation in the cytosol. Based on published data, evidence
from studies of human mitochondrial proteomes (Smith et al.,
2012) and our unpublished predictions, we estimate that 250–300
nuclear-encoded proteins are dedicated to serve mitochondrial
gene expression.
Numerous genetic defects can lead to perturbations of the
OXPHOS system and result in multi-system, often fatal, human
diseases. These mutations can be located within nDNA or
mtDNA. Isolated OXPHOS deficiencies, that affect a specific bio-
chemical activity of the OXPHOS system, are usually caused
by mutations in structural genes (coding for a specific compo-
nent of the OXPHOS machinery) or in genes encoding pro-
teins responsible for the assembly of a particular respiratory
complex. In contrast, inherited pathological mutations, affect-
ing either mitochondrially or nuclearly encoded components
of the mitochondrial gene expression machinery, are generally
associated with combined OXPHOS deficiencies affecting mul-
tiple enzymes involved in cellular respiration. Many mutations
in the mtDNA-encoded RNA components of the mitochondrial
translation apparatus (mt-rRNAs andmt-tRNAs) have been iden-
tified, and detection of yet uncharacterised mutations is relatively
straightforward. In contrast, a class of mutations in nuclear gene
products involved in proper maintenance of the mitochondrial
transcriptome that are linked to human disease has emerged only
in recent years. This group currently contains approximately 40
genes (Nicholls et al., 2013; Boczonadi and Horvath, 2014).
This special-issue review focuses on a subset of nuclear-
encoded factors involved in mitochondrial gene expression, for
which genetic variants impacting upon mitochondrial patho-
physiology have been reported. In particular, we survey the
known proteins involved in post-transcriptional nucleolytic pro-
cessing and nucleotide modifications of mitochondrial tRNAs
(Figure 1). Key primary pathological mtDNA mutations with
recognized effects upon mt-tRNA nucleolytic processing and
modifications are also briefly described. Although we recog-
nize the recent discoveries of the key role of mitochondrial
aminoacyl-tRNA synthetases (mtARSs) in human pathology
affecting mitochondrial translation, this group of disease genes
is not covered by the review. Existing recent papers extensively
describe the mitochondrial pathologies caused by genetic defects
in ARSs (Konovalova and Tyynismaa, 2013; Diodato et al., 2014;
Vanlander et al., 2014), including a comprehensive evaluation of
the tissue-specificity aspect of ARS mutations presented in this
special issue (Euro et al., 2015).
Processing of mt-tRNA
The two strands of mtDNA are almost entirely transcribed as
single polycistronic units from the heavy- and light-strand pro-
moters, HSP and LSP. Transcription from the heavy strand
results in a large precursor that encodes 2 rRNAs, 14 tRNAs,
and 12 proteins, whereas the light strand codes for eight tRNAs
and one mRNA. In these long precursor transcripts, most mRNA
and rRNA genes are flanked by tRNAs, whose cloverleaf struc-
tures act as recognition elements for endonucleolytic cleavage in
order to release individual mtRNA molecules (Anderson et al.,
1981; Ojala et al., 1981). Removal of 5′ RNA leaders is carried
out by mitochondrial RNase P (Holzmann et al., 2008), while 3′
leaders are removed by an RNase Z activity, which is contributed
by ELAC2 (Brzezniak et al., 2011; Figure 1). Four mtRNA junc-
tions are not flanked by tRNA genes, and thus do not conform
to this paradigm. RNase P has been suggested to be responsible
for cleavage of the 5′ end of the CO1 gene (despite the absence
of its typical recognition element; Lopez Sanchez et al., 2011),
and additional factors are likely required for processing of the
remaining junctions.
5′-End Processing of mt-tRNA:
Mitochondrial Protein Only RNase P
The majority of RNases P discovered thus far are ribozymes,
containing a catalytic RNA molecule. Mammalian mitochon-
drial RNase P, in sharp contrast, is a three-protein complex
lacking RNA, apparently assembled from proteins appropriated
from other biochemical pathways during evolution to func-
tion in tRNA cleavage. These three proteins are: MRPP1 (also
known as TRMT10C or RG9MTD1), which is one of three ver-
tebrate homologs of the yeast tRNA-methyltransferase Trm10;
MRPP2 (also known as HSD10 or SDR5C1), a protein of
the short-chain dehydrogenase/reductase family also involved
in isoleucine metabolism; and MRPP3, a metallonuclease-like
protein putatively containing the active site of the RNase P
complex (Holzmann et al., 2008). MRPP1 and MRPP2 together
form a stable subcomplex that also participates in tRNA base
modification (discussed in a later section), while the more
labile association of MRPP3 completes the RNase P complex
(Vilardo et al., 2012). Mutations in MRPP2, encoded by the
HSD17B10 gene on the X-chromosome, are associated with a
childhood neurodegenerative disorder, with a number of muta-
tions having been described with varying severity and age of
onset (Zschocke et al., 2000; Ofman et al., 2003). A recent study
has observed uncleaved precursor mtRNAs in fibroblasts from
patients with MRPP2 mutations, as well as in siRNA-treated
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FIGURE 1 | Mitochondrial RNA maturation and factors involved.
Key protein factors involved in post-transcriptional nucleolytic processing and in
chemical modifications of mitochondrial tRNAs. Factors associated with human
disease are indicated in red; other factors characterized thus far are in blue.
Note: PNPase can be either directly or indirectly involved in mt-tRNA processing
(red question mark). The bacterial homologs of MTO1 and GTPBP3 form a
complex, however, the interaction between the human proteins has not been
shown (question mark).
cultured cells (Deutschmann et al., 2014), consistent with the loss
of RNase P activity contributing to the disease progression.
3′-End Processig of mt-tRNA: ELAC2
Mammals possess two orthologs of the prototypical bacte-
rial RNase Z elaC; a short form (ELAC1) and a long form
(ELAC2), both of which are capable of endonucleolytically pro-
cessing tRNAs in vitro (Takaku et al., 2003). ELAC1 predomi-
nantly localizes to the cytosol, whereas ELAC2 is targeted both
to mitochondria and to the nucleus (Rossmanith, 2011). siRNA
downregulation of ELAC2 expression results in an accumula-
tion of 3′ unprocessed mt-tRNA precursors, confirming that
ELAC2 is the mitochondrial RNase Z (Brzezniak et al., 2011;
Lopez Sanchez et al., 2011). ELAC2 has also been found to asso-
ciate with the pentatricopeptide repeat (PPR) domain-containing
protein PTCD2, which makes a poorly understood contribution
to mt-tRNA processing (Lopez Sanchez et al., 2011). Mutations
in ELAC2 have been associated with mitochondrial disease in
five individuals suffering from an infantile-onset hypertrophic
cardiomyopathy and complex I deficiency (Haack et al., 2013).
Analysis of patient muscle and fibroblasts revealed a mtRNA
processing defect and strongly impaired translation, linking
mtRNA processing with the mitochondrial translation machinery
(Haack et al., 2013). This highlights the importance of maintain-
ing a correct balance between precursor and mature mtRNAs
for proper gene expression in mitochondria, and these aspects
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require further investigation. In addition to being implicated in
mitochondrial disease, ELAC2 is also an established susceptibility
gene for prostate cancer (Tavtigian et al., 2001).
PNPase: A Special Case
A third mitochondrial disease locus with possible links to RNA
processing is polynucleotide phosphorylase, PNPase. A propor-
tion of the cellular PNPase pool localizes to the mitochon-
drial matrix, where it interacts with the RNA helicase SUV3
and participates in mtRNA degradation, possibly of antisense
mtRNA molecules (Minczuk et al., 2002; Piwowarski et al., 2003;
Nagaike et al., 2005; Borowski et al., 2010, 2013; Szczesny et al.,
2010; Chujo et al., 2012). The majority of cellular PNPase, how-
ever, localizes to the mitochondrial intermembrane space, spa-
tially separating PNPase from its mtRNA substrates (Chen et al.,
2006). This pool of PNPase has a highly unusual proposed role
in the import of a small number of cytosolic RNA molecules
into the mitochondrial matrix, namely RNase P RNA (the RNA
component of the nuclear RNase P ribozyme, suggested to con-
stitute an additional mitochondrial RNase P activity), MRP RNA
(hypothesized to be involved in primer formation for mtDNA
replication) and 5S cytosolic ribosomal RNA (Wang et al., 2010).
The consolidation of these observations with other available data
is problematic, however, as (i) the amounts of detectable nuclear
RNase P RNA within mitochondria (Puranam and Attardi, 2001)
have been suggested to be too low to be functionally rele-
vant (Rossmanith, 2012), while the protein components of the
nuclear RNase P complex have also not been found in mito-
chondria in proteomic studies (e.g., Pagliarini et al., 2008) (ii)
MRP RNA has been found to be localized almost exclusively
in the nucleolus, with negligible quantities within mitochondria
(Kiss and Filipowicz, 1992), and (iii) recent structures of the large
mitoribosomal subunit have confirmed that cytosolic 5S rRNA
is not a component of the mitoribosome, its role having been
replaced by a mt-tRNA (Brown et al., 2014; Greber et al., 2014).
Recessive mutations in the PNPT1 gene, encoding PNPase,
were recently linked to human mitochondrial disease in two sib-
lings affected by encephalomyopathy, choreoathetosis, and com-
bined OXPHOS deficiency, and in three siblings from a second
family affected by non-syndromic hearing loss (Vedrenne et al.,
2012; von Ameln et al., 2012). In both reports the mutations
interfered with the normal oligomerization of PNPase, and the
PNPase-mediated import of cytosolic RNAs into mitochondria
was found to be impaired. The authors suggested that perturbed
import of RNase P RNA impairs the activity of the putative mito-
chondrially localized nuclear RNase P ribozyme, and thereby
inhibit mt-tRNA processing. The effect of these pathological
mutations upon matrix mtRNA processing would provide an
interesting basis for future study.
Post-Transcriptional Modifications of
Mitochondrial tRNA
The 22 mt-tRNAs act as key adaptor molecules between the
mRNAs transcribed from mtDNA and the 13 subunits of the
OXPHOS complexes, which they encode. As with all known
tRNAs, they undergo numerous post-transcriptional nucleotide
modifications prior to becoming active elements in protein trans-
lation in mitochondria (Suzuki et al., 2011). Chemical modifi-
cations are crucial for tRNA structure and stability and also
ensure the efficiency and stringent accuracy that is required dur-
ing decoding in mitochondrial translation. Mitochondrial tRNA
modifying enzymes represent an expanding group of mitochon-
drial disease causing genes, which we survey below and sum-
marized in Figure 2 and Table 1. We also briefly describe other
identified mt-tRNA modifiers (Table 1).
Polymerases
Almost all eukaryotic tRNA genes, along with many archaeal and
bacterial tRNA genes, encode an RNA molecule that lacks cru-
cial nucleotides from the fully matured tRNA following cleavage
from the precursor RNA. Further polymerization is subsequently
required to produce the full length tRNA, with the same process
often utilized for the repair of damaged tRNA ends.
TRNT1
The universally conserved CCA sequence found on the 3′ ter-
minus of all tRNAs represents the major post-transcriptional
polymerization event involved in the maturation process. Once
matured, the newly polymerized 3′ terminus acts as the amino
acid attachment site, catalyzed by the cognate aminoacyl-tRNA
synthetase. Studies on in vitro transcribed tRNAs have reported
that the CCA sequence acts as a tRNase Z anti-determinant,
ensuring that a futile cycle between polymerase and ribonucle-
ase activities does not occur (Mohan et al., 1999). Additionally,
the CCA sequence existing in the form of a tandem CCACCA on
the 3′ end has been identified as a quality control signal, targeting
misfolded or hypomodified tRNAs for degradation (Wilusz et al.,
2011). In human mitochondria, polymerization at the 3′ termi-
nus of tRNAs is performed by the essential enzyme, TRNT1
(tRNA-nucleotidyltransferase 1), in a non-templated reaction
(Nagaike et al., 2001). Despite the lack of any template to spec-
ify the sequence with which nucleotides need to be incorporated,
TRNT1 exhibits extremely high selectivity for its CTP and ATP
substrates, in the correct order, with precise termination follow-
ing the completion of the CCA sequence. Primary mitochondrial
disorders as a consequence of impaired CCA-addition have been
known for some time, resulting from mutations affecting either
the catalytic rate (m.4317A > G in tRNAIle; Tomari et al., 2003)
or the substrate binding strength (m.3303C> T in tRNALeu(UUR) ;
Levinger et al., 2004). Recently, a cohort of patients exhibiting
SIFD (Sideroblastic anemia associated with immunodeficiency,
periodic fevers and developmental delay) were reported to carry
mutations in TRNT1, with the range of clinical severity correlat-
ing with the degree of TRNT1 loss of function (Chakraborty et al.,
2014). The role of mitochondrial dysfunction in congenital sider-
oblastic anemia has beenwell demonstrated, with causative muta-
tions found in genes involved in haem synthesis, mitochondrial
iron–sulfur biogenesis, and mitochondrial translation (Fleming,
2011). The phenotypic pleiotropy observed in SIFDmay be a con-
sequence of the dual localization of TRNT1 resulting in impaired
cytosolic as well as mitochondrial translation.
Frontiers in Genetics | www.frontiersin.org 4 March 2015 | Volume 6 | Article 79
Powell et al. Mitochondrial tRNA and human disease
FIGURE 2 | Chemical modifications of mitochondrial tRNA. Schematics of
the “clover leaf” secondary structure of a generic mitochondrial tRNA indicating
post-transcriptionally modified bases (circles). The details of the chemical
modification and enzyme responsible (if known) for each tRNA position is given
in boxes, indicating a tRNA base position number next to each box. The
chemical modifications identified in mammalian species other than human are in
brackets. Color coding: red, enzyme responsible for the modification has been
associated with human disease; blue, enzyme responsible for particular
modification has been identified; gray, modifying enzyme has not been
identified.
THG1L
Despite the overwhelming preference among polymerases for 5′-
3′ synthesis, as occurs during the CCA-addition described above,
a unique case of 3′-5′ polymerization is utilized to catalyze the
addition of an uncoded guanine onto the 5′ end of tRNAHis.
This additional 5′-guanylate (G−1), a signature characteristic of
tRNAHis molecules from all but a handful of species, is simply
encoded in the genome of bacteria and many archaea, whereas in
eukaryotes it is, in most cases, added post-transcriptionally by a
member of the tRNA-histidine guanyltransferase 1 (Thg1) family.
G−1 has been shown to serve as an important discrimination ele-
ment for its cognate histidine aminoacyl-tRNA synthetase, with
depletion of the yeast Thg1 being followed by a concomitant
diminished aminoacylation rate. In humans, the mitochondrial
tRNAHis gene does not encode for an additional 5′-guanine, and a
member of the Thg1-family has been predicted within the nuclear
genome (Nakamura et al., 2013), which may represent a candi-
date gene for mitochondrial diseases due to its critical role in
translation efficiency.
Methyltransferases
Of the plethora of modifications identified in mitochondrial
tRNAs, methylation represents the most abundant and diverse
grouping, being found at a wide range of different loca-
tions within a tRNA, as well as at different positions within
a given base. Depending on the nature of the modification
and the location of the residue, methylations within tRNAs
have been implicated in structural stabilization, a decrease in
the likelihood of frameshifting, and in improving translation
efficiency.
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TRMT1
The first identified human tRNA methyltransferase, TRMT1,
was found to be responsible for both the m2G26 and m22G26
tRNA methylations based on the activity of the recombinant
protein in vivo in Escherichia coli cells expressing human cytoso-
lic tRNATyr (Liu and Straby, 2000). The predicted mitochondrial
targeting sequence, along with the mitochondrial localization of
the yeast homolog, Trm1 (Ellis et al., 1989), has lead to the con-
clusion that TRMT1 is responsible for the m22G26 modification
found in humanmitochondrial tRNAs. A homozygous frameshift
mutation predicted to completely inactivate TRMT1 has been
reported in a family with non-syndromic intellectual disability
(Najmabadi et al., 2011).
TRMT5
The recombinant protein approach has also been utilized to
characterize a second human tRNA methyltransferase, TRMT5,
which was found to catalyze the formation of m1G37 in vitro
for a number of tRNA substrates, including human mitochon-
drial tRNAPro (Brule et al., 2004). In both yeast and bacteria, the
m1G37 modification has been shown to play a critical role in pre-
venting frameshifting errors at the ribosome (Urbonavicius et al.,
2001).
TRMT61B
The N1-methylation of adenosine at position 58, which confers
stabilization to the tertiary structure of the tRNA (Robertus et al.,
1974), has been identified in three human mitochondrial tRNAs:
Leu(UUR), Lys, and Ser(UCN). Through a combination of in
vitro and in vivo analysis, m1A58 has been recognized as the
product of a mitochondria-specific methyltransferase, TRMT61B
(Chujo and Suzuki, 2012).
TRMT10C (MRPP1)
As mentioned previously, a subcomplex of RNase P performs
a tRNA modifying role entirely separate from the endonucle-
olytic cleavage of the complex as a whole. The N1-methylation
of purines at position 9 (R9) is carried out by a complex
of MRPP1 (also known as TRMT10C), a homolog of yeast
tRNA:m1R9 methyltransferase Trm10, and MRPP2 (also known
as SDR5C1 or HSD10), a dehydrogenase whose exact role in the
R9 methylation complex remains unknown (Vilardo et al., 2012).
Methylation of position 9 has been demonstrated to play a crit-
ical role in tRNA structure, being both necessary (Sakurai et al.,
2005) and sufficient (Helm et al., 1999) for the correct folding
of a tRNA. Patients with HSD10 disease, caused by mutations
in MRPP2, present with progressive neurological abnormalities
and cardiomyopathy and also have depleted levels of TRMT10C.
However, the potential involvement of diminishedm1R9 in mito-
chondrial tRNAs in the pathomechanism of HSD10 disease has
yet to be demonstrated (Deutschmann et al., 2014).
Pseudouridine Synthetases
The isomerization of uracil produces the most abundant of
the modifications so far described; pseudouridine ( , or 5-
ribosyluracil), which is bestowed with unique chemical properties
largely thanks to an additional hydrogen bond donor on its
non-Watson Crick edge which often acts to rigidify an RNA
structure (Davis, 1995; Newby and Greenbaum, 2002) and con-
tributes toward the stabilization of a particular structural motif.
The in situ isomerization of uracil is performed by members
of the pseudouridine synthase family, which exhibit remarkably
high specificity for their target residues. For this reason, organ-
isms typically utilize a large number of pseudouridine synthase
proteins in order to target the wide range of pseudouridyla-
tion sites within their substrate RNAs. Of the 13 pseudouridine
synthases found in humans, PUS1 is by far the most well char-
acterized, and has been found to be responsible for 27 and
28 in mitochondrial tRNAs (Patton et al., 2005), as well as cat-
alyzing the formation of  in a number of other non-coding
RNAs (e.g., Zhao et al., 2004). Loss of function mutations in
PUS1, along with a concordant decreased rate of mitochon-
drial translation, have been identified in a number of patients
with myopathy, lactic acidosis and sideroblastic anemia (MLASA;
Patton et al., 2005; Zeharia et al., 2005; Fernandez-Vizarra et al.,
2007). Studies in yeast and E. coli have provided candidate genes
for the remaining pseudouridine sites found in human mito-
chondrial tRNAs, such as PUS6 for 31 (Ansmant et al., 2001),
PUS9 for 32 (Behm-Ansmant et al., 2004), TRUB2 for 55
(Becker et al., 1997; Zucchini et al., 2003), and PUS3 for 39 and
40 (Lecointe et al., 1998), however, the enzymatic role of these
proteins have yet to be demonstrated in humans. In contrast
to the stabilizing effects of pseudouridylation, uridine may also
be modified to dihydrouridine (D), allowing for greater confor-
mational flexibility through the saturation of its base (Dalluge,
1996). The human enzyme DUS2 is proposed to introduce D20
into mitochondrial tRNAs based on yeast homology (Xing et al.,
2004), and has been implicated in pulmonary carcinogenesis
(Kato et al., 2005).
Taurine Modification Enzymes (MTO1 AND
GTPBP3) and Thiouridylase (MTU1 aka
TRMU): A Special Case
Non-canonical base pairing at position 34, also known as
the wobble base, allows for the expansion of the codon-
recognition capabilities of a tRNA and therefore all possi-
ble codons to be decoded. As a consequence of this critical
function, position 34 is one of the most frequently modified
nucleosides, with a wide variety of modification chemistries,
in order to specify unusual base pairing features. The mod-
ification at position 34 in mammalian mt-tRNAs commonly
involves the incorporation of taurine onto an encoded uri-
dine in the form of 5-taurinomethyluridine (τm5U) found in
mammalian tRNALeu(UUR), tRNATrp, tRNALys, tRNAGln, and
tRNAGlu (Suzuki and Suzuki, 2014). Interestingly, pathogenic
mutations in tRNALeu(UUR) (3243 and 3271) and tRNALys (8344)
that are known to cause MELAS and MERRF, respectively, are
found to dramatically diminish the level of the U34 modification
in the corresponding tRNA (Suzuki et al., 2002). It is postu-
lated that these mutations disrupt the recognition determinants
utilized by the enzyme(s) responsible for the synthesis of the
modification, with the resulting impairment of codon recog-
nition being the primary cause of disease (Kirino et al., 2005,
2006), however, the definitive identification of the responsible
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enzymatic activity has yet to be demonstrated in humans. Studies
in bacteria and yeast mitochondria have greatly assisted efforts
due to the high evolutionary conservation of the enzymes
involved, despite the fact that both incorporate a carboxymethy-
laminomethyl (cmnm) group in place of taurine. In E. coli,
MnmE and GidA form a heterodimeric complex that catalyzes
the formation of cmnm at position 5 of the wobble uridine
(Moukadiri et al., 2009), as do the related mitochondrially local-
ized MSS1 and MTO1 in yeast. The human homologs have
been identified as GTPBP3 and MTO1 (Li and Guan, 2002;
Li et al., 2002), both of which have been localized to mitochon-
dria and are able to complement mitochondrial phenotypes in
corresponding yeast deletion strains. More recently, patients
exhibiting hypertrophic cardiomyopathy and lactic acidosis as
a consequence of a combined respiratory chain deficiency have
been found to carry mutations in MTO1 (Ghezzi et al., 2012;
Baruffini et al., 2013) and GTPBP3 (Kopajtich et al., 2014). An
association of MTO1 mutations with impaired mitochondrial
translation remains to be shown for human cells. However,
the striking similarity in clinical presentation suggests a com-
mon pathomechanism related to the U34 modification for both
diseases. Notably, in addition to hypertrophic cardiomyopa-
thy, lactic acidosis, and combined OXPHOS deficiency, some
patients with GTPBP3 mutations also developed encephalopa-
thy (Kopajtich et al., 2014). Through linkage analysis, both
MTO1 and GTPBP3 have also been implicated as modi-
fier genes of a homoplasmic mitochondrial deafness-associated
m1555A > G mutation within 12S rRNA (Bykhovskaya et al.,
2004). m.1555A > G presents with a broad range of pheno-
typic severity, the variance of which is believed to be influ-
enced by the inheritance of nuclear-encoded modifier genes
(Bykhovskaya et al., 1998). Interestingly, a m.1477C > G muta-
tion disrupting the corresponding base pair in yeast 15S rRNA
was found to be required in combination with MSS1 and MTO1
mutants in order to cause respiratory deficiency (Decoster et al.,
1993; Colby et al., 1998).
Of the five tRNAs previously discussed as substrates of MTO1
and GTPBP3, three of these, tRNALys, tRNAGln, and tRNAGlu,
undergo further modification on the wobble base to produce
5-taurinomethyl-2-thiouridine (τm5s2U) (Suzuki et al., 2002). A
thiouridylase, MTU1 (also known as TRMU), catalyzes the
formation of the 2-thio group in mitochondrial tRNAs, with
its depletion resulting in their dramatically reduced thiolation
(Umeda et al., 2005; Sasarman et al., 2011). The formation of
2-thiouridine is also proposed to be dependent on a cysteine
desulfurase, NFS1, a component of the Fe/S cluster assembly
machinery, for supplying the sulfur atom (Nakai et al., 2004).
Mutations in MTU1, as well as those within its substrate tRNA,
have been found in a large number of individuals presenting
with reversible infantile respiratory chain deficiency, character-
ized by acute liver failure (Zeharia et al., 2009; Schara et al., 2011;
Uusimaa et al., 2011; Gaignard et al., 2013). Limited sulfur avail-
ability during the neonatal period has been proposed as the
explanation for the spontaneous recovery of patients following
a window of vulnerability, and cysteine supplementation dur-
ing this period may act as a potential treatment (Boczonadi et al.,
2013).
Other tRNA-Modifying Enzymatic Activities
The anticodon loop is a hotspot for post-transcriptional modifi-
cations, and harbors the greatest range of modifications within
the tRNA, predominantly at positions 34 and 37. Position 34
undergoes a greater range of modifications than those so far
described, an observation in line with its critical role in the fine-
tuning of codon recognition. The ability of wobble base modifi-
cations to drastically alter codon–anticodon interactions is clearly
illustrated in the case of 5-formylcytidine (f5C34) in mt-tRNAMet
(Moriya et al., 1994). In the cytosol, a single codon, AUG, encodes
for methionine and is recognized by two different tRNAs, one for
initiation and one for elongation (Mayer et al., 2001). In mito-
chondria, however, methionine encoding is expanded to AUA,
as well as AUG, with both codons being recognized by a sin-
gle tRNA bearing a CAU anticodon (Bilbille et al., 2011). The
modification of C34 to f5C34 is believed to expand the codon
recognition capabilities of tRNAMet through enhanced binding
to AUA (Lusic et al., 2008; Takemoto et al., 2009). The enzymatic
activity responsible for f5C34 formation has yet to be iden-
tified. The final modified base thus far found at position 34
of human mitochondrial tRNAs, queuosine (Q), represents an
interesting case in which rather than an encoded base being mod-
ified in situ, the entire base (in this case a guanine) is excised
and replaced through a breakage of the glycosidic bond. The
substitution of guanine for Q is performed by tRNA-guanine
transglycosylases (TGTases), with QTRTD1, one of two mam-
malian TGTases, believed to perform the reaction in human
mitochondria (Boland et al., 2009; Chen et al., 2010). Aswith pre-
vious wobble base modifications, Q34 has been implicated in
modifying the decoding capabilities of a tRNA (Morris et al.,
1999).
Position 37, a purine in all human mt-tRNAs, is methy-
lated in the case of guanine, as mentioned above. A37 on
the other hand is commonly modified through the addition
of an isopentenyl group, and the resulting i6A37 promotes
translational efficiency and fidelity through increased decod-
ing stringency, with its loss resulting in mitochondrial dys-
function in yeast (Lamichhane et al., 2013a). The tRNA isopen-
tenyltransferase responsible for i6A37 formation in humans,
TRIT1, was initially identified as a tumor suppressor gene
(Spinola et al., 2005), and its siRNA-mediated depletion causes
diminished i6A37 in mitochondrial tRNAs (Lamichhane et al.,
2013b). Mutations in TRIT1, with a corresponding loss of
the i6A modification and compromised mitochondrial transla-
tion, have been identified in siblings with encephalopathy and
myoclonic epilepsy (Yarham et al., 2014). A subset of TRIT1
substrates are further modified through the action of a mito-
chondrially localized methylthiotransferase, CDK5RAP1, to form
ms2i6A37 (Reiter et al., 2012). The final modification found at
position 37 in human mitochondrial tRNAs, threonylcarbamoyl
adenosine (t6A), has also been demonstrated to play a critical
role in maintaining decoding accuracy (Stuart et al., 2000). Its
biosynthetic pathway in humans remains unknown, however,
with YRDC and OSGEPL1, the human homologs of the yeast
N(6)-threonylcarbamoyltransferases Sua5 and Qri7, respectively,
being the most likely candidates (Oberto et al., 2009; Wan et al.,
2013).
Frontiers in Genetics | www.frontiersin.org 8 March 2015 | Volume 6 | Article 79
Powell et al. Mitochondrial tRNA and human disease
Methionyl-tRNA Formyltransferase
(MTFMT): Special Case
Although not a chemical modification of tRNA sensu stricto, it
is worth mentioning that mt-tRNAMet is also formylated on the
methionine amino acid charged to the 3′ end to form fMet-
tRNAMet, which increases its affinity toward the mitochondrial
initiation factor (IF2mt; Takeuchi et al., 1998). Mutations in mito-
chondrial methionyl-tRNA formyltransferase (MTFMT) have
been identified in a number of patients presenting with mito-
chondrial encephalomyopathy (Tucker et al., 2011; Neeve et al.,
2013; Haack et al., 2014).
Primary mtDNA Mutations Affecting
RNA Processing and
Post-Transcriptional Modifications
It is important to note that defects in mtRNA processing by
nuclear-encoded mitochondrial enzymes may also result from
mutations in the RNA substrate itself, if recognition or cleavage
of the RNA by the processing machinery is impaired. However,
while mutations in the nDNA involved in mtRNA processing,
as described above, would be expected to interfere with all
mtRNA processing events, primary mtDNA mutations would
only be expected the affect the mtRNA bearing the mutation.
The multi-copy nature of the mitochondrial genome also
means that mutant and wild-type genomes coexist within a
cell (heteroplasmy) with clinical phenotypes only manifest-
ing above a threshold level of typically 80–90% of mutated
genomes. Pathological mutations in mt-tRNA genes are the
most frequent among all mtDNA mutations (Yarham et al.,
2010). Given the structural determinants of post-transcriptional
mt-tRNA nucleolytic processing and modification, many of
these mutations are likely to destabilize tRNA structure and
interfere with these processes. Below we present some examples
of pathogenic point mutations in mt-tRNA genes that have
been linked to a mtRNA processing or modification defect.
The m.4308G > A mutation in the mt-tRNAIle gene has been
found to cause chronic progressive external ophthalmoplegia
(CPEO). This mutation is believed to destabilize the secondary
structure of the tRNA, making the tRNA a poor substrate for 3′
end processing by ELAC2 (Schaller et al., 2011). A number of
well-studied mutations in the mt-tRNALeu(UUR) gene, frequently
associated with mitochondrial myopathy, encephalopathy,
lactic acidosis, and stroke-like episodes (MELAS), have also
been found to interfere with precursor mtRNA processing.
Disease-associated point mutations in mt-tRNALeu(UUR) have
been found to impair RNaseP and ELAC2-mediated tRNA
cleavage both in vitro (Rossmanith and Karwan, 1998) as well
as in transmitochondrial cybrids and in patient fibroblasts
(Bindoff et al., 1993; Levinger et al., 2004). However, a num-
ber of other molecular defects have also been reported for
mt-tRNALeu(UUR) carrying MELAS-associated point muta-
tions, such as decreased aminoacylation (Chomyn et al., 2000),
decreased CCA-addition (Levinger et al., 2004), structural
defects (Wittenhagen and Kelley, 2002), decreased stability, and
loss of post-transcriptional modification of the wobble-base
(Yasukawa et al., 2000). It is therefore very difficult to determine
how each of these factors contributes to the overall patho-
physiology of the mutation, as the observed processing defect
may merely be a side-effect of the impaired folding or post-
transcriptional processing/modification of the tRNA. This
complicated relationship between mt-tRNA point mutations
and post-transcriptional events implies that a detailed analysis
of mt-tRNA processing and modifications could be helpful
in elucidating the pathomechanism of particular mt-tRNA
mutations.
mt-tRNA Metabolism and Tissue
Specificity of Disease
The above survey shows that pathological mutations in mito-
chondrial tRNA processing and modifying enzymes are numer-
ous and result in divergent clinical phenotypes. Organ specificity
of the observed pathological symptoms is an important feature of
these cases (e.g., for mutations in GTPBP3 and MTO1 – mostly
heart, in TRIT1 – brain and in MTU1 – liver). This is unex-
pected given that any defect in mt-tRNA metabolism should,
in principle, perturb only a single cellular process, which is
mitochondrial translation. The molecular mechanisms behind
this phenomenon are largely unknown. Below we discuss key
aspects of mtRNA metabolism and possible outcomes associ-
ated with defective mt-tRNA biology that might be helpful when
formulating new hypotheses on the different clinical presenta-
tions of mt-tRNA-related genetic defects (Figure 3).
According to recent data, approximately 25 tRNA posi-
tions contain modified nucleotides in mammalian mitochon-
dria. Some key tRNA positions, such as 34 and 37 (Figure 2),
contain different modifications depending upon the mt-tRNA
species. Therefore, is has been estimated that over 30 mito-
chondrial enzymes are required for introducing these modifica-
tions (Suzuki and Suzuki, 2014). The tissue-specific distribution
and/or activity of these enzymes are expected to be different. Also,
cellular distribution may vary between enzymes, with, for exam-
ple, PUS1 and TRIT1 being localized to both the nucleus and
mitochondria (see above). The same may apply to the nucleases
responsible for mt-tRNA cleavage from the primary transcript. As
a consequence, organ-specific regulation of the level of specific
mt-tRNA modifications and the concentration of certain mt-
tRNA species is expected to take place. Furthermore, given
the chemical intricacy of mt-tRNA modifications (for example
τm5s2U or ms2i6A, Figure 2), biosynthesis of the cofactors to
be introduced into the mt-tRNA molecules rely on a number of
apparently unrelated biochemical pathways. This links the mt-
tRNA modifications to metabolic properties of certain tissues,
where the availability of individual substrates might be consid-
erably different, thereby indirectly influencing protein synthesis
in mitochondria. Moreover, the molecular genetics of mtDNA
maintenance and expression may have a key role in regulat-
ing the properties of a mt-tRNA population. The segregation of
mtDNA heteroplasmy is known to be tissue-dependent, which is
of great importance for the clinical outcomes in the case of the
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FIGURE 3 | Mitochondrial tRNA metabolism and tissue specificity of
associated disease. Several properties that relate to tissue-specific
regulation of mitochondrial tRNA biology by nuclearly- (green) and
mitochondrially encoded genes (red) are listed to the left. Possible
genetic defect leading to perturbations of mitochondrial tRNA metabolism
resulting from mutations in the nuclear (nDNA) or mitochondrial genome
(mtDNA) are shown in the center. The tissue specific regulation of the
mt-tRNA maturation pathways in conjunction with nDNA or mtDNA
mutations can give rise to the cell type-specific molecular phenotypes
listed to the right.
primary mtDNA mutations in mt-tRNA genes. Also, the rate of
mtRNA synthesis and decay is different in various human cell
types, regulating the specific concentration of mt-tRNAs.
Given the above tissue-specificity of the intrinsic features gov-
erning mt-tRNA biology, genetic defects either in the nDNA
coding for mt-tRNA processing or modifying enzymes or in
mitochondrial tRNA genes can be expected to have cell type-
specific consequences. Several molecular scenarios might be
envisaged for this to happen (Figure 3). For example, chemical
modification of tRNA nucleotides are often crucial for stabil-
ity, with hypomodified tRNAs being targeted for degradation
(Alexandrov et al., 2006). Thus a genetic defect in a mt-tRNA
modifier responsible for stabilizing mt-tRNA may result in cell
type-specific RNA decay leading to local mt-tRNA insufficiency.
For example, the binding of protein partners may act to stabilize
an otherwise unstable tRNA, as has been demonstrated for the
m.3243A > G mutation in mt-tRNALeu(UUR) (Perli et al., 2014)
or the m.1624C > T mutation in mt-tRNAVal (Hornig-Do et al.,
2014) following the overexpression of a non-catalytic portion
of LARS2. Tissue specificity may then result from the loss of
a stabilizing mt-tRNA modification due to differing expression
levels of these protein partners among tissue types. Another
instance may occur for a pathogenic mutation that partially
inactivates a mt-tRNA modifier, combined with a tissue-specific
availability of a cofactor used by this enzyme. In such a scenario
the pathological outcome of this mutation will be more devas-
tating in cofactor-poor tissues, leading, for example, to defects in
mitochondrial translation accuracy and efficiency (as proposed
for sulfur availability and MTU1 – see above). Furthermore,
tissues with high demands for mt-tRNA expression might be
more affected by mutations in mt-tRNA processing or modifying
enzymes owing to their reduced activity. In some cases, the lack of
modification of certain mt-tRNAs might affect the translation of
only a subset of mitochondrial transcripts that are rich in codons
recognized by this particular mt-tRNA. In such a situation iso-
lated, rather than combined, OXPHOS deficiency might be pro-
duced. Lastly, tissue-specific segregation of pathological mtDNA
mutations affecting mt-tRNA has been well documented since
the origin of mitochondrial medicine. As mentioned above, these
mutations can affect processing or modification of mt-tRNAs. It
is conceivable that particular tissue might be severely affected as a
compound effect of high mt-tRNA mutation load in conjunction
with low activity of enzymes responsible for maturation of this
impaired substrate mt-tRNA.
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Concluding Remarks and Future
Directions
Recent research has revealed the important role of mitochon-
drial tRNApost-transcriptional nucleolytic processing and chem-
ical modifications in human disease (Figures 1 and 2; Table 1).
However, the mechanistic details for the origin of pathologies
associated with defects inmt-tRNA biology remain poorly under-
stood (Figure 3).
It is now time to intensify efforts on elucidating the
molecular machinery and mechanisms responsible for regu-
lating post-transcriptional stages of mt-tRNA biology. Given
that over 30 different modifications to mammalian mt-tRNAs
have been described so far, with only 10 enzymes responsi-
ble for their synthesis being currently described (Figure 2),
special attention should be given to assigning the remain-
ing two-thirds of mt-tRNA modifiers. This point is particu-
larly important for mitochondrial medicine, as despite recent
advances in next-generation sequencing technologies, defining
the genetic architecture of the many unsolved cases of mito-
chondrial disease remains a major challenge. Further research
should also concentrate on revealing the consequences of the
presence of hypomodified or incorrectly processed mt-tRNAs
on mitochondrial protein synthesis. To address this, it will be
essential to apply novel technologies such asmitoribosome profil-
ing based on next-generation sequencing of RNA (Rooijers et al.,
2013) and/or on mass spectrometry (Wessels et al., 2013). It
will also be important to analyze which mt-tRNA muta-
tions, the most common class of pathogenic mtDNA muta-
tion, affect post-transcriptional processing and modification.
This research will help to understand the remarkable het-
erogeneity of human pathologies associated with defects of
mt-tRNA metabolism. It is also our belief that these efforts
will stimulate further studies aimed at the development of
novel therapeutics based on modulation of mt-tRNA pro-
cessing and, in particular, modification, leading to effec-
tive treatments for these otherwise untreatable mitochondrial
diseases.
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